2012-09-17 07:20:26 - v Fast Market Research recommends "Enterococcus Faecium Infections - Pipeline Review, H2 2012" from Global Markets Direct, now available

Global Markets Direct's, 'Enterococcus Faecium Infections - Pipeline Review, H2 2012', provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. 'Enterococcus Faecium Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.


Full Report Details at
- www.fastmr.com/prod/463785_enterococcus_faecium_infections_pipel ..


Scope

* A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections.
* A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Enterococcus Faecium Infections therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Enterococcus Faecium Infections Therapeutic Products under Development, Key Players in Enterococcus Faecium Infections Therapeutics, Enterococcus Faecium Infections Pipeline Overview, Enterococcus Faecium Infections Pipeline, Enterococcus Faecium Infections Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Enterococcus Faecium Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Enterococcus Faecium Infections
Enterococcus Faecium Infections Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Enterococcus Faecium Infections Therapeutics - Products under Development by Companies
Companies Involved in Enterococcus Faecium Infections Therapeutics Development
Ceragenix Pharmaceuticals, Inc.
Piramal Healthcare Limited
Nabi Biopharmaceuticals
Wockhardt Limited
Paratek Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc.
Lorus Therapeutics Inc
Oragenics, Inc.
MerLion Pharmaceuticals Pte Ltd
Aquapharm Biodiscovery Limited
MicuRx Pharmaceuticals, Inc.
Trius Therapeutics, Inc.
Enterococcus Faecium Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
LOR-220 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omadacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibiotic Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MU1140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipopeptide Programme - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EnteroVAX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PM181104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tedizolid Phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipopeptide Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSA-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463785&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.